Raloxifene hydrochloride is a Small Molecule owned by Eli Lilly and Co, and is involved in 17 clinical trials, of which 15 were completed, and 2 are ongoing.
Raloxifene is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM), reproduces the beneficial effects of estrogens on the skeletal systems, without the negative effects estrogens on breast and endometrium. Raloxifene appears to act as an estrogen agonist in bone. It decreases bone resorption and bone turnover, increases bone mineral density (BMD) and decreases fracture incidence.
The revenue for Raloxifene hydrochloride is expected to reach a total of $265m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Raloxifene hydrochloride NPV Report.
Raloxifene hydrochloride is originated and owned by Eli Lilly and Co.
Raloxifene hydrochloride Overview
Raloxifene hydrochloride (Evista/ Optruma) is a benzothiazipine derivative, acts as an anti-osteoporotic agent. It is formulated as tablets and film coated tablets for oral route of administration. Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women and for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and women at high risk of invasive breast cancer. Raloxifene hydrochloride was also under development for the treatment of hereditary hemorrhagic telangiectasia in the U.S and EU.
Eli Lilly and Co Overview
Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.
The company reported revenues of (US Dollars) US$28,318.4 million for the fiscal year ended December 2021 (FY2021), an increase of 15.4% over FY2020. In FY2021, the company’s operating margin was 21%, compared to an operating margin of 24.7% in FY2020. In FY2021, the company recorded a net margin of 19.7%, compared to a net margin of 25.2% in FY2020. The company reported revenues of US$6,941.6 million for the third quarter ended September 2022, an increase of 7% over the previous quarter.
Quick View – Raloxifene hydrochloride
|Highest Development Stage|